When the supplementary materials of a study recently published by Mehta et al. are examined, a predominant driver of both the primary (cardiovascular death or new myocardial infarction [MI]) and co-primary endpoints (cardiovascular death, new MI, or ischemia-driven revascularization [IDR]) is the reduction of Type 1 non-ST elevation myocardial infarction (NSTEMI). STEMI rates were comparable, but NSTEMI rates differed significantly (3% vs. 5%), along with fewer Type 1 NSTEMIs noted in the complete group (3% vs. 6%).